Emodin can inhibit the recruitment of inflammatory cells in the tumor microenvironment, such as CD11b+ and F4/80+, reduce cytokines, such as TNFα, IL1α/β, IL6, CCL2, and CXCL5, and inhibit COX-2 and NOS2 to inhibit the active adhesion, migration and invasion of CRC cells 108. Here, CCL2 is linked to neoplasm.